Praxis medicines to present at 36th international epilepsy congress 2025 in lisbon, showcasing latest radiant study data and leading precision epilepsy pipeline

Boston, aug. 25, 2025 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (cns) disorders, today announced its participation in the upcoming international epilepsy congress (iec), taking place august 30–september 3, 2025, in lisbon, portugal.
PRAX Ratings Summary
PRAX Quant Ranking